Results of gestational trophoblastic neoplasia treatment in the Slovak Republic in the years from 1993 to 2012

Česká verzia

Authors: M. Korbeľ ^1,2; J. Šufliarsky ^1,3; Ľudovít Danihel ^1,4; J. Vojtaššák ^1,5; Z. Nižňanská ^1,2
Authors place of work: Centrum pre gestačnú trofoblastovú chorobu Ministerstva zdravotníctva Slovenskej republiky, Bratislava ¹
Published in the journal: Ceska Gynekol 2016; 81(1): 6-13

Summary

Objective:
Analysis and epidemiology of gestational trophoblastic neoplasia treatment in the Slovak Republic in the years 1993–2012.

Design:
Retrospective epidemiological national study.

Setting:
Centre for gestational trophoblastic disease Ministry of Health the Slovak Republic, Bratislava.

Methods:
Retrospective analysis results of gestational trophoblastic neoplasia treatment according to prognostic scoring and staging system FIGO/WHO in Centre for gestational trophoblastic disease Ministry of Health the Slovak Republic Bratislava in the years 1993–2012.

Results:
The treatment of gestational trophoblastic neoplasia (GTN) in the Czech and Slovak Republics started in 1955 and lasted till 1993. After the split of the former Czechoslovakia the Centre for gestational trophoblastic disease was created in Slovakia. 75 patients were treated in this Centre in the years 1993–2012. According to prognostic scoring and staging system FIGO/WHO 56 (75%) patients had low-risk gestational trophoblastic neoplasia and 19 (25%) of patients had high-risk gestational trophoblastic neoplasia. There were 41 patients (55%), 2 (3%), 24 (32%) and 8 (11%) in stage I., II., III. and IV. respectively. Total curability rate was 94.7% and mortality rate was 5.3%. Curability rate 100% was achieved in stage I & II and all placental site trophoblastic tumours (PSTT), 98.3% in stage III and 50% stage IV. In the years 1993–2012 the incidence of choriocarcinoma was one in 76 273 pregnancies and one in 53 203 deliveries. The incidence of other gestational trophoblastic neoplasia in the same years was for PSTT one in 533 753 pregnancies and one in 372 422 deliveries, invasive mole one in 145 611 pregnancies and one in 101 569 deliveries, and persistent GTN one in 40 043 pregnancies and one in 27 932 deliveries. 225–241 patients were treated in the same period of time in the Czech Republic with curability rate 98.2–98. 3%.

Conclusion:
Early detection and treatment in the centre for trophoblastic disease are crucial points in the management of gestational trophoblastic neoplasia, because the effective therapy of gestational trophoblastic neoplasia with high curability rate is available.

KEYWORDS:
gestational trophoblastic neoplasia, choriocarcinoma, placental site trophoblastic tumour, invasive mole, epidemiology, treatment

Zdroje

1. Bolze, P-A., Attia, J., Massardier, J., et al. Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases. Eur J Cancer, 2015, 51, 13, p. 1725–1731.

2. Danihel, Ľ., Čierna, Z., Šišovský, V., et al. Histopatologická diagnostika gestačných trofoblastových tumorov. Gynekol prax, 2014, 12, 3, s. 150–153.

3. FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. Int J Gynecol Obstet, 2000, 77, 3, p. 285–287.

4. Gazárek, F., Kudela, M., Lindner, E. Naše zkušenosti s léčbou choriokarcinomu. Čs Gynek, 1976, 41, s. 273–275.

5. Genest, DR., Berkowitz, RS., Fisher, RA, et al. Gestational trophoblastic disease. In: Tavassoli, FA., Devilee, P. WHO classification of tumours, pathology and genetics, tumours of the breast and female genital organs. tumours of the uterine corpus. Lyon: IARC Press, 2003, p. 250–254.

6. Hernandez, E. Gestational trophoblastic neoplasia. Updated, 2010, Mar 16. http://emedicine.medscape.com.

7. Hron, F. Výsledky léčby gestačních trofoblastických tumorů v ČR. Liptovský deň gynekologickej onkológie SLS SGPS. 9.11.2013 Lúčky, SR.

8. Hron, F., Feyereisl, J., Zavadil, M. Výsledky léčby gestačních trofoblastických tumorů v ČR. Gynekol prax, 2014, 12, 3, s. 127–131.

9. Hron, F, Hejda, V, Feyereisl, J., et al. Quiscent trophoblastic disease. Čes Gynek, 2011, 76, 6, s. 443–446.

10. Kohorn, EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report. J Reprod Med, 2002, 47, 6, p. 445–500.

11. Korbeľ, M., Danihel, Ľ., Vojtaššák, J., et al. Centrum pre trofoblastovú chorobu Slovenskej republiky – 10 rokov činnosti. Slov Gynek Pôrod, 2003, 10, 2, s. 56–61.

12. Korbeľ, M., Šufliarsky, J., Danihel, Ľ., et al. Liečba gestačných trofoblastových tumorov v Slovenskej republike v rokoch 1993–2012. Gynekol prax, 2014, 12, 3, s. 132–135.

13. Kudela, M., Gazárek, F., Fingerova, H. Diagnostik und Terapie bösartiger Trofoblasttumoren. Acta Univ Palacky Olom, 1979, 90, s. 213–216.

14. Kudela, M., Talaš, M., Fingerova, H. Současné možnosti prevence a terapie trofoblastické nemoci. Čs Gynek, 1981, 46, s. 108–111.

15. Kudela, M., Fingerova, H., Podivínský, J. Choriokarcinom komplikovaný mozkovou metastázou. Čs Gynek, 1983, 48, s. 31–39.

16. Kudela, M., Fingerova, H., Tichý, M., Talandová, A. Choriocarcinoma in pregnancy. Case report. Acta Univ Palacky Olom, 1984, 107, s. 367–371.

17. Li, MC., Hertz, R., Spencer, DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Biol Med, 1956, 93, p. 361–369.

18. Mangili, G., Lorusso, D., Brown, J., et al. Trophoblastic disease review for diagnosis and management. Int J Gynecol Cancer, 2014, 24, S3, p. S109–S116.

19. Mogensen, B. Invasive mole and gestational choriocarcinoma in Denmark, 1940–1969: biological and clinical aspects. Acta Obstet Gynec Scand, 1973, 52, 3, p. 211–220.

20. Ngan, HYS., Seckl, MJ., Berkowitz, RS., et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynecol Obstet, 2015, 131, suppl, s. S123 – S126.

21. RCOG. The management of gestational trophoblastic disease. RCOG Green-top Guideline No. 38, february 2010.

22. Rob, L., Bauer, J., Citterbart, K., et al. Chirurgická léčba gestační trofoblastické nemoci. Čes Gynek, 1993, 58, 2, s. 80–84.

23. Rob, L., Zavadil, M., Vlachová, J. Těhotenství po chemoterapii u maligních forem gestační trofoblastické nemoci. Sborník lékařský, 1993, 94, 2, s.185–189.

24. Rob, L., Robová, H., Pluta, M., Kačírek, J. Gestační trofoblastická nemoc. Mod Gynek Porod, 2000, 9, s. 706–716.

25. Rob, L., Robová, H., Pluta, M., et al. Regrese hladin hCG u různých typů molárního těhotenství – klinický průběh a prognóza. Čes Gynek, 2001, 66, 4, s. 230–235.

26. Rob, L. Gestačná trofoblastová neoplázia liečená na gynekologicko-pôrodníckej klinike v Motole v rokoch 1996–2012. Nepublikované údaje – osobné informácie. Október 2015.

27. Seckl, MJ., Sebire, NJ., Berkowitz, RS. Gestational trophoblastic disease. Lancet, 2010, 376, 9742, p. 717–729.

28. Seckl, MJ., Sebire, NJ., Fischer, RA., et al. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnostisis, treatment and follow-up. Ann Oncol, 2013, 24, 6, p. vi39–vi50.

29. Skřivan, J., Zavadil, M., Jakoubková, J., et al. Péče o ženy s trofoblastickou nemocí (choriokarcinomem) v ČSSR. Prakt Lék, 1982, 62, s. 546–547.

30. Soper, JT. Gestational trophoblastic disease. Obstet Gynecol, 2006, 108, 1, p. 176–187.

31. Šufliarsky, J., Korbeľ, M., Bartošová, I., et al. Chemoterapia gestačných trofoblastových tumorov. Gynekol prax, 2014, 12, 3, s. 136–140.

32. Talaš, M., Fingerova, H., Kudela, M. hCG podjednotky u choriokarcinomu a v těhotenství. Acta Univ Palack Olom, 1977, 84, s. 311–317.

33. WHO. Gestational trophoblastic diseases: report of a WHO scientific group. WHO Tech Rep Ser, 1983, 692:, p. 51.

34. Zavadil, M., Skřivan, J., Rob, L., et al. Centrum pro trofoblastickou nemoc (CTN). Čs Gynek, 1988, 53, s. 695–700.

35. Zavadil, M., Skřivan, J., Vlachová, J., Rob, L. Léčebně preventivní péče u trofoblastické nemoci v ČSSR. Čas Lék čes, 128, 1989, 19, s. 586–589.

36. Zavadil, M., Feyereisl, J., Krofta, L., et al. Perzistující trofoblastická nemoc v Centru pro trofoblastickopu nemoc v ČR v letech 1955–2007. Čes Gynek, 2008, 73, 2, s. 73–79.